Tropocells® PRFM
(Platelet Rich Fibrin Matrix) is a fibrin gel matrix that is derived by combining Tropocells® PRP with autologous thrombin. Tropocells® TRS (Thrombin Rich Serum) is a major byproduct of Tropocells® PRF.
PRFM produced by PRP activation with TRS, provides a flexible platform that enables control of PRP concentration. Platelet concentration of at least one million/microliter is considered therapeutically effective. The platelet concentration affects the matrix viscosity and different growth factor release patterns. PRP activation with autologous thrombin shows an immediate release of PDGF and TGF that remains stable over time. VEGF demonstrates an increasing trend from 15 minutes up to 24 hours. PRFM platform enables also the control over the matrix diameter.
By combining Tropocells® TRS with Tropocells® PRP, physicians can obtain Growth Factors Rich Fibrin (GFRF) in the form of either injectable GFRF* or GFRF** membrane.
*GFRG -Growth Factors Rich Gel
**GFRF – Growth Factors Rich Fibrin
Why TropoCells® PRFM?
- Better stability of grafted tissue
- Faster vascularization
- Increases tissue generation due to growth factors release
- Improves and hastens healing and regeneration; including epithelial wound healing – recovery is nearly 6 times faster
- Jump starts osteogenesis
- Faster preparation of implant site
- Lower infection risk which helps to avoid further inflammation, complications, pain and post-operation discomfort
- Decreased pre/post-operation bleeding
- Safe and convenience
- No risk of rejection being an autologous material
Preparation
